New technologies are announced almost daily, so what makes SynDevRx different? Our technology increases the activity of small molecule drugs by about 10x, allowing for reduced doses, lower exposure and lower risk of toxicities.
We believe our compounds are the next generation of drug therapies. They combine a highly active moieties conjugated to stable, bio-compatible polymers using proprietary techniques. Restricting drug release to disease tissue concentrates activity where needed while reducing the risk of toxicities.
For more information, please contact:
VP Business Development
NB: SynDevRx is not affiliated with Children's Hospital Boston, and has no development program associated with Children's Hospital.